Italian drugmaker Angelini Pharma has closed its $4.1 billion acquisition of Catalyst Pharmaceuticals, a US-based rare-disease company, paying $31.50 per share. The deal gives the family-owned company a ready-made US business, including Catalyst's commercial team and its portfolio of medicines for hard-to-treat conditions. But the financing structure is drawing as much attention as the acquisition itself.
How the Deal Was Financed
Angelini funded the purchase with a mix of equity and debt. CDP Equity, the investment arm of Italian state-backed lender Cassa Depositi e Prestiti, invested about €1 billion in a capital increase, taking a 23.5% stake in Angelini. Separately, funds managed by Blackstone added roughly €1 billion in preferred equity, a type of funding that sits between common stock and debt. Preferred equity typically gets paid before common shareholders in a liquidation, and it can act as a buffer for lenders if the business underperforms.
That buffer helped Angelini secure a syndicated loan from a group of 14 banks led by BNP Paribas, which rounded out the financing package. The structure allowed Angelini to fund a large US acquisition without giving up control, a key consideration for a family-owned company.
What Angelini Gets
Catalyst Pharmaceuticals specializes in rare diseases, a segment of the drug market that often commands high prices and faces less competition than broader therapeutic areas. The company's lead product is Firdapse, a treatment for Lambert-Eaton myasthenic syndrome, a rare neuromuscular disorder. Catalyst also has a pipeline of other rare-disease candidates.
For Angelini, the acquisition provides an immediate US commercial presence, something the company has lacked. Angelini has long focused on neurology and mental health, and the deal gives it a platform to expand into other hard-to-treat conditions. The company said the acquisition supports its strategy of building a global specialty pharmaceutical business.
Why the Financing Structure Matters
The involvement of CDP and Blackstone highlights a growing trend in cross-border dealmaking. Family-owned European companies often struggle to finance large US acquisitions because they are reluctant to dilute their ownership by selling common shares. Preferred equity offers a middle ground: it provides equity-like funding without the same control implications.
Because preferred holders typically take losses before lenders do, banks view the structure as lower risk. That can support larger loans and tighter terms, making it easier to finance big deals. If this playbook proves repeatable, preferred equity could become a regular tool for family-owned European buyers trying to compete for US assets, particularly in the pharmaceutical and biotech sectors.
This deal is part of a broader wave of consolidation in the pharmaceutical industry, as companies seek to bolster their pipelines and expand into new markets. For more on recent M&A activity, see Dealmakers Reshape Pharma, Robotics, and Delivery with Multi-Billion Takeovers.
What It Means for Investors
For everyday investors, the deal is a reminder that how a company finances an acquisition can be as important as the acquisition itself. The use of preferred equity and state-backed capital reduced the risk for the lending banks, which likely helped Angelini secure more favorable loan terms. That, in turn, made the deal possible.
Investors in Catalyst Pharmaceuticals received $31.50 per share, a premium to the stock's trading price before the deal was announced. For Angelini, which is privately held, the deal does not directly affect public markets. But the financing structure could influence how other European companies approach US acquisitions, potentially leading to more cross-border deals in the pharmaceutical sector.
The involvement of CDP, a state-backed lender, also raises questions about the role of government in corporate dealmaking. While CDP's investment is a minority stake, it gives the Italian state a say in Angelini's strategy. That could be a positive for investors who see state backing as a sign of stability, or a concern for those who worry about political influence.
For a broader look at recent pharma deals, see Angelini Pharma Closes $4.1B Catalyst Buyout with State and Blackstone Backing.
What to Watch Next
Investors will be watching to see whether Angelini can successfully integrate Catalyst and use its US platform to launch new products. The company has said it plans to expand in neurology and other hard-to-treat conditions, which could mean more acquisitions or partnerships down the line.
The success of the financing structure could also encourage other family-owned European companies to pursue similar deals. If preferred equity becomes a standard tool for cross-border M&A, it could reshape the landscape for pharmaceutical dealmaking. For more on how M&A is reshaping industries, see ABB's $5.5 Billion Cash Deal for Rotork Is Its Largest Acquisition Ever.
In the meantime, the deal is a reminder that the pharmaceutical industry remains a hotbed of M&A activity, as companies race to secure new drugs and expand their geographic reach. For investors, understanding the financing behind these deals is key to assessing their long-term impact.
